Morgan Stanley Believes Myriad Genetics (NASDAQ: MYGN) Won’t Stop Here

By Carrie Williams

In a report released today, Steve Beuchaw from Morgan Stanley maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN), with a price target of $49. The company’s shares closed yesterday at $42.84, close to its 52-week high of $44.87.

According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 13.8% and a 61.0% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Danaher Corp, and Align Tech.

Myriad Genetics has an analyst consensus of Hold, with a price target consensus of $41.

See today’s analyst top recommended stocks >>

The company has a one-year high of $44.87 and a one-year low of $27.23. Currently, Myriad Genetics has an average volume of 728K.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. Last month, Richard M. Marsh, the E.V.P., General Counsel of MYGN sold 70,672 shares for a total of $3,029,968.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other.